If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Company Update

5 Jul 2013 07:00

RNS Number : 6665I
Ark Therapeutics Group PLC
05 July 2013
 



Ark Therapeutics Group plc

 

Company Update

 

London, UK, 5 July 2013 - Ark Therapeutics Group plc (LSE: AKT) ("Ark") has been notified by Crawford Healthcare Ltd ("Crawford") that it is of the view that certain sales of its products (KerraMax Care) do not constitute relevant sales for the purposes of the earn-out consideration due to Ark (subject to certain revenue targets) under the sale agreement dated 7 February 2011 pursuant to which Ark's woundcare business was sold to Crawford Woundcare Limited. As such, in Crawford's view it is unlikely that the revenue targets will be met in respect of calendar year 2013. Ark strongly disagrees with the position Crawford is attempting to assert and, having taken legal advice, is confident that the product sales in question should be included in the relevant revenue targets which may or may not trigger earn-out consideration. Whilst any payment to Ark of deferred consideration remains subject to the agreed revenue targets being met in calendar year 2013, and as such no guarantee can be given as to the likelihood of those targets being met, Ark is confident that on the basis of advice its position is sound and it will take all steps available to it to protect its contractual rights.

 

Non-Executive Director, David Venables, comments:

 

"We were initially contacted by Crawford Healthcare to discuss their position in April and since then the Company has taken independent legal advice on the detail of the contract. Discussions continue, and we hope to resolve the matter amicably with Crawford Healthcare."

 

A further update will be provided in due course.

 

For further information please contact:

 

Ark Therapeutics Group plc

Tel: +44 (0)207 002 1005 

 

Iain G Ross, Non-Executive Chairman

 

David Venables, Non-Executive Director

 

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding Ark's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond Ark's control that could cause the actual results, performance or achievements of Ark to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding Ark's present and future business strategies and the environment in which Ark will operate in the future. These forward-looking statements speak only as at the date of this announcement. Ark expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in Ark's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFETDDISIIV
Date   Source Headline
19th May 20087:00 amRNSResearch Update
16th May 20087:00 amRNSInterim Management Statement
24th Apr 20084:57 pmRNSAGM Results
22nd Apr 20087:00 amRNSRegulatory Update
17th Apr 20087:00 amRNSProduct Update
1st Apr 20083:26 pmRNSAnnual Information Update
31st Mar 200812:39 pmRNSTotal Voting Rights
28th Mar 20081:46 pmRNSRe Appointment
20th Mar 20087:00 amRNSBoard Appointment
11th Mar 20087:01 amRNSLaunch of Neuropad
11th Mar 20087:01 amRNSFinal Results
5th Mar 20085:20 pmRNSHolding(s) in Company
13th Feb 20087:00 amRNSManufacturing Update
31st Jan 200810:27 amRNSVoting Rights and Capital
23rd Jan 20084:56 pmRNSNotice of Results
18th Jan 20087:01 amRNSResearch Update
17th Jan 200810:42 amRNSRe: Employee Benefit Trust
11th Jan 200810:33 amRNSDirector/PDMR Shareholding
9th Jan 20084:50 pmRNSResignation of NED
8th Jan 20087:00 amRNSAcquisition
19th Dec 20074:37 pmRNSPrice Monitoring Extension
6th Dec 20075:48 pmRNSHolding(s) in Company
5th Dec 20071:39 pmRNSHolding(s) in Company
5th Dec 200712:41 pmRNSHolding(s) in Company
4th Dec 20075:40 pmRNSBlocklisting Interim Review
4th Dec 20074:56 pmRNSBlocklisting Interim Review
4th Dec 200711:50 amRNSHolding(s) in Company
30th Nov 200712:35 pmRNSDirector/PDMR Shareholding
30th Nov 200712:10 pmRNSVoting Rights and Capital
29th Nov 20072:17 pmRNSResult of EGM
28th Nov 20074:27 pmRNSRe: Placing and Open Offer
6th Nov 20077:01 amRNSPlacing and Open Offer
30th Oct 20075:08 pmRNSHolding(s) in Company
25th Oct 20077:01 amRNSResearch Update
22nd Oct 20071:01 pmRNSHolding(s) in Company
16th Oct 20073:23 pmRNSHolding(s) in Company
10th Oct 20077:01 amRNSRe Agreement
8th Oct 20077:00 amRNSRe Agreement
28th Sep 20073:06 pmRNSVoting Rights and Capital
31st Aug 200710:39 amRNSVoting Rights and Capital
29th Aug 20077:01 amRNSInterim Results
20th Aug 20077:02 amRNSRe: Product Launch
31st Jul 200711:23 amRNSVoting Rights and Capital
26th Jul 20077:01 amRNSResearch Update
24th Jul 200711:18 amRNSNotice of Results
23rd Jul 20077:01 amRNSRe: Cerepro
6th Jul 20077:00 amRNSEPO Grant Stroke Patent
29th Jun 20071:14 pmRNSVoting Rights and Capital
22nd Jun 20074:03 pmRNSHolding(s) in Company
15th Jun 20072:45 pmRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.